Literature DB >> 29109606

Pegvisomant for acromegaly.

.   

Abstract

Entities:  

Year:  2017        PMID: 29109606      PMCID: PMC5662428          DOI: 10.18773/austprescr.2017.065

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


× No keyword cloud information.
  3 in total

1.  Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

Authors:  P J Trainer; W M Drake; L Katznelson; P U Freda; V Herman-Bonert; A J van der Lely; E V Dimaraki; P M Stewart; K E Friend; M L Vance; G M Besser; J A Scarlett; M O Thorner; C Parkinson; A Klibanski; J S Powell; A L Barkan; M C Sheppard; M Malsonado; D R Rose; D R Clemmons; G Johannsson; B A Bengtsson; S Stavrou; D L Kleinberg; D M Cook; L S Phillips; M Bidlingmaier; C J Strasburger; S Hackett; K Zib; W F Bennett; R J Davis
Journal:  N Engl J Med       Date:  2000-04-20       Impact factor: 91.245

2.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

3.  Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.

Authors:  Pamela U Freda; Murray B Gordon; Nicky Kelepouris; Peter Jonsson; Maria Koltowska-Haggstrom; A J van der Lely
Journal:  Endocr Pract       Date:  2015-03       Impact factor: 3.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.